4-Bromo-3-fluoro-2-nitroanisole|CS-0212296|1352317-80-6

4-Bromo-3-fluoro-2-nitroanisole

$49.50

FREE
SHIPPING

100% MONEY
BACK GUARANTEE

ONLINE
SUPPORT 24/7

Available on backorder. No lead time available. Please request a quote.
Sku TS246CS-0212296_250_MG
ChemScene
Get Bulk Quote

Product Information

Product Name
4-Bromo-3-fluoro-2-nitroanisole
Brand Name
ChemScene
Product Number
CS-0212296
CAS
1352317-80-6
Certificate of Analysis (COA)​
COA not found

General Information

PubChem CID
56776542
IUPAC Name
1-bromo-2-fluoro-4-methoxy-3-nitrobenzene
InChI Key
LJJAOMRFFXQENV-UHFFFAOYSA-N
SMILES
COC1=C(C(=C(C=C1)Br)F)N+(=O)O-

References

Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Anti-invasive therapeutic in Head and neck squamous cell carcinoma
Publication Name: Oral Oncology
Publication Date: 2022-09
DOI: 10.1016/j.oraloncology.2022.106008

A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma
Publication Name: Scientific Reports
Publication Date: 2022-06-30
DOI: 10.1038/s41598-022-13801-1

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
Publication Name: Journal for ImmunoTherapy of Cancer
Publication Date: 2022-01
DOI: 10.1136/jitc-2021-003518

Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
Publication Name: Journal for ImmunoTherapy of Cancer
Publication Date: 2021-12
DOI: 10.1136/jitc-2021-003580

Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)
Publication Name: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication Date: 2021-03-20
DOI: 10.1200/jco.20.02755